Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM

Trial Profile

DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Sleep bruxism
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2018 New trial record
    • 17 Jan 2018 Primary endpoint efficacy as assessed by clinical global impressions (CGIs)) has been met, according to results published in the Neurology.
    • 17 Jan 2018 Results assessing safety and efficacy of onabotulinum toxin-A (BoNT-A) injections into the masseter and temporalis muscles in patients with symptomatic sleep bruxism, were published in the Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top